Merck Completes Acquisition of Cidara Therapeutics in $9.2 Billion Deal

Merck has finalized its $9.2 billion acquisition of Cidara Therapeutics, incorporating Cidara's late-stage antiviral drug CD388 into its pipeline. This acquisition aims to broaden Merck's portfolio in infectious diseases, with CD388 potentially offering a universal flu prevention option. The tender offer was completed at $221.50 per share.